Technical Data
IL-13, Recombinant, Cotton Rat, 5-His-Tag, Carrier Free (Interleukin 13, IL13)
Molecular Biology Storage: -20CShipping: Blue Ice
IL-13 is a 17kD immunoregulatory cytokine that plays a key role in the pathogenesis of allergic asthma and atopy. It is secreted by Th1 and Th2 CD4+ T cells, NK cells, visceral smooth muscle cells, eosinophils, mast cells, and basophils. IL-13 circulates as a monomer with two internal disulfide bonds that contribute to a bundled four A-helix configuration. Mature cotton rat IL-13 shares 59%, 74%, and 72% aa sequence identity with human, mouse, and rat IL-13, respectively. Despite the low homology, it exhibits cross-species activity between human, mouse, and rat. IL-13 has diverse activities on numerous cell types. On macrophages, IL-13 suppresses the production of proinflammatory cytokines and other cytotoxic substances. On B cells, IL-13 induces immunoglobulin class switching to IgE, up-regulates the expression of MHC class II, CD71, CD72, and CD23, and costimulates proliferation. IL-13 up-regulates IL-6 while down-regulating IL-1 and TNF-A production by fibroblasts and endothelial cells. IL-13 binds with low affinity to IL-13 RA1, triggering IL-13 RA1 association with IL-4 RA. This high affinity receptor complex also functions as the type 2 IL-4 receptor complex. Additionally, IL-13 binds with high affinity to IL-13 RA2 which is expressed intracellularly, on the cell surface, and as a soluble molecule. IL-13 RA2 regulates the bioavailability of both IL-13 and IL-4 and is overexpressed in glioma and several bronchial pathologies. Compared to wild type IL-13, the atopy-associated R110Q variant of IL-13 elicits increased responsiveness from eosinophils that express low levels of IL-13 RA2.

Recombinant corresponding to aa1-133 from cotton rat IL-13, fused to 5-His-tag at C-terminal expressed in CHO cell line.

Molecular Weight:

Biological Activity:
Measured in a cell proliferation assay using TF-1 human erythroleukemic cells. The ED50 for this effect is typically 3-18mg/ml

Endotoxin: ~1EU/1ug (LAL)

Storage and Stability:
Lyophilized powder may be stored at -20C. Stable for 12 months at -20C. Aliquot to avoid repeated freezing and thawing. Store at -20C. Reconstituted product is stable for 3 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Molecular Weight:
Source: CHO cells
Purity: ~95% (SDS-PAGE)
Concentration: ~0.1mg/ml after reconstitution
Form: Supplied as a lyophilized powder in PBS. BSA free. Reconstitute with sterile PBS to 0.1mg/ml.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Wills-Karp, M.(2004)Immunol. Rev. 202:175. 2. Nakajima H. and K. Takatsu (2007) Int. Arch. AllergyImmunol. 142:265. 3. McKenzie, A.N. et al. (1993) Proc. Natl. Acad. Sci. 90:3735. 4. Blanco, J.C.G. et al. (2004) J. Interferon Cytokine Res. 24:21. 5. Moy, F.J. et al. (2001) J. Mol. Biol. 310:219. 6. `Eisenmesser, E.Z. et al. (2001) J. Mol. Biol. 310:231. 7. Ruetten, H. and C. Thiemermann (1997) Shock 8:409. 8.Lakkis, F.G. et al. (1997) Biochem. Biophys. Res. Commun.235:529. 9. Wynn, T.A. (2003) Annu. Rev. Immunol. 21:425.10. Andrews, A.L. et al. (2002) J. Biol. Chem. 277:46073. 11.Tabata, Y. et al. (2007) Curr. Allergy Asthma Rep. 7:338. 12. Chiaramonte, M.G. et al. (2003) J. Exp. Med. 197:687. 13. Daines, M.O. and G.K. Hershey (2002) J. Biol. Chem. 227:10387. 14. Matsumura, M. et al. (2007) Biochem. Biophys. Res. Commun. 360:464. 15. Tabata, Y. et al. (2007) J. Immunol. 177:7905. 16. Andrews, A.L. et al. (2006) J. Allergy Clin. Immunol.118:858. 17. Joshi, B.H. et al. (2006) Vitam. Horm. 74:479. 18.Andrews, A.-L. et al. (2007) J. Allergy Clin. Immunol.120:91.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.